In addition, there are also some studies about ASO therapeutics by targeting exon restoration, including nusinersen for spinal muscular atrophy, oligonucleotide‐induced alternative splicing of serotonin 2C receptor (Claborn et al., 2019; Zhang et al., 2016). The gene discussed is HTR2C; the disease is proximal spinal muscular atrophy.